CU20150071A7 - Composición de liberación demorada que comprende biguanida - Google Patents

Composición de liberación demorada que comprende biguanida

Info

Publication number
CU20150071A7
CU20150071A7 CUP2015000071A CU20150071A CU20150071A7 CU 20150071 A7 CU20150071 A7 CU 20150071A7 CU P2015000071 A CUP2015000071 A CU P2015000071A CU 20150071 A CU20150071 A CU 20150071A CU 20150071 A7 CU20150071 A7 CU 20150071A7
Authority
CU
Cuba
Prior art keywords
biguanida
understanding
composition
delayed release
delayed
Prior art date
Application number
CUP2015000071A
Other languages
English (en)
Spanish (es)
Inventor
Alain D Baron
Mark S Fineman
Terri Kim
Stephen Kwaku Dordunoo
Original Assignee
Elcelyx Terapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50030486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20150071(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elcelyx Terapeutics filed Critical Elcelyx Terapeutics
Publication of CU20150071A7 publication Critical patent/CU20150071A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CUP2015000071A 2013-01-05 2015-07-06 Composición de liberación demorada que comprende biguanida CU20150071A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361749307P 2013-01-05 2013-01-05
PCT/US2014/010240 WO2014107617A1 (en) 2013-01-05 2014-01-03 Delayed-release composition comprising biguanide

Publications (1)

Publication Number Publication Date
CU20150071A7 true CU20150071A7 (es) 2016-01-29

Family

ID=50030486

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2015000071A CU20150071A7 (es) 2013-01-05 2015-07-06 Composición de liberación demorada que comprende biguanida

Country Status (19)

Country Link
US (3) US20140193498A1 (enExample)
EP (2) EP2941245B1 (enExample)
JP (1) JP6333855B2 (enExample)
KR (1) KR102229492B1 (enExample)
CN (2) CN105101956B (enExample)
AR (1) AR094374A1 (enExample)
AU (1) AU2014203942B2 (enExample)
CA (1) CA2896864C (enExample)
CL (1) CL2015001914A1 (enExample)
CU (1) CU20150071A7 (enExample)
EA (1) EA039530B1 (enExample)
HK (1) HK1214966A1 (enExample)
IL (1) IL239722B (enExample)
MX (2) MX389344B (enExample)
NZ (1) NZ709525A (enExample)
PH (1) PH12015501520A1 (enExample)
SG (2) SG11201505240QA (enExample)
WO (1) WO2014107617A1 (enExample)
ZA (1) ZA201504858B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
PT2661266T (pt) 2011-01-07 2020-11-30 Anji Pharma Us Llc Terapias com base em ligandos do recetor quimiossensorial
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
SG10201901922VA (en) 2012-01-06 2019-04-29 Elcelyx Therapeutics Inc Compositions and methods for treating metabolic disorders
MX2014008190A (es) 2012-01-06 2015-02-04 Elcelyx Therapeutics Inc Composiciones de biguanida y métodos para tratar transtornos metabólicos.
FI3236943T3 (fi) * 2014-12-24 2023-04-27 Principia Biopharma Inc Koostumuksia ileo-jejunaaliseen lääkkeenantoon
US10744070B2 (en) 2015-06-19 2020-08-18 University Of Southern California Enteral fast access tract platform system
US10631564B2 (en) 2015-06-19 2020-04-28 University Of Southern California Enterically coated microparticle compositions and methods for modified nutrient delivery
WO2018132768A1 (en) * 2017-01-13 2018-07-19 Sanna Pietro P Methods and compositions for treating hpa hyperactivity
FR3068601B1 (fr) * 2017-07-05 2021-02-19 Eric Joseph Marie Fulgence Janin Utilisation de l'imeglimine pour la prevention et/ou le traitement du carcinome hepatocellulaire
KR20220024189A (ko) * 2019-06-03 2022-03-03 알.피.쉐러 테크놀러지즈 엘엘씨 지연 방출 소프트젤 캡슐
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
US20230000820A1 (en) * 2021-06-28 2023-01-05 ImmunoMet Therapeutics, Inc. Solid dosage form of n-1-pyrrolidine-n-5-(3-trifluoromethoxy)phenyl biguanide and uses thereof
CN119499203A (zh) 2023-08-22 2025-02-25 雅研(天津)生物医药科技中心(有限合伙) 一种盐酸二甲双胍肠溶片
CN119499228B (zh) 2023-08-22 2026-04-03 雅研(天津)生物医药科技中心(有限合伙) 盐酸二甲双胍肠溶制剂
US12599544B2 (en) 2024-05-09 2026-04-14 Alsteni Medical, Inc. Intraoral gastrointestinal access device and related methods
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1209253A (en) 1913-01-09 1916-12-19 Automatic Electric Co Impulse-transmitting device.
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
JPS58403B2 (ja) 1975-07-24 1983-01-06 武田薬品工業株式会社 Ｌ− アスコルビンサンセイザイノ セイゾウホウ
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5135757A (en) 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
FR2704146B1 (fr) 1993-04-19 1995-07-13 Cripdom Microcapsules d'acide acétylsalicylique à libération contrôlée.
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
FR2725623A1 (fr) 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
ATE422359T1 (de) 1997-04-15 2009-02-15 Csir Verbindungen und pharmazeutische zusammensetzungen mit appetitunterdrückender aktivität
US5891919A (en) 1997-09-19 1999-04-06 Burlington Bio-Medical & Scientific Corp. Denatonium capsaicinate and methods of producing the same
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
ITMI991316A1 (it) 1999-06-14 2000-12-14 Cip Ninety Two 92 S A Composizioni farmaceutiche orali a rilascio modificato di mesalazina
IL132313A0 (en) 1999-10-11 2001-03-19 Yeda Res & Dev Leptin assay
US20110217394A1 (en) 2000-12-05 2011-09-08 Brett Justin West Iridoid Based Formulations
CA2725833A1 (en) * 2001-01-12 2002-07-18 Sun Pharmaceutical Industries Limited Spaced drug delivery system
AU2002307217A1 (en) 2001-03-28 2002-10-15 University Of South Florida Materials and methods for treatment of cancer and identification of anti-cancer compounds
US8030008B2 (en) 2001-04-05 2011-10-04 Senomyx, Inc. Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US6830759B2 (en) * 2002-06-28 2004-12-14 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration
US20060019346A1 (en) 2002-07-29 2006-01-26 Senomyx, Inc. Identification of a novel bitter taste receptor T2R76 that specifically responds to brucine and prop bitter ligands
CA2494281A1 (en) * 2002-08-02 2004-02-12 Penwest Pharmaceuticals Company Sustained release formulations of metformin
CN1413582A (zh) * 2002-11-29 2003-04-30 贵州圣济堂制药有限公司 盐酸二甲双胍肠溶片及其制备方法
JP4654038B2 (ja) 2002-12-18 2011-03-16 ジボダン エス エー キメラアルファｑ−ガストデューシンｇタンパク質
DE10308504A1 (de) 2003-02-26 2004-09-09 Basf Ag Enzymatische Herstellung von (Meth)acrylsäureestern
WO2005009351A2 (en) 2003-07-17 2005-02-03 Santé International, Inc. Dietary supplement for promoting control of blood-sugar levels and associated pathology in type 2 diabetics
JP4812752B2 (ja) 2004-04-20 2011-11-09 ドイチェス インシュティテュート フェア エルネールングスフォルシュング 苦味受容体のアゴニストおよびその使用
US20060024335A1 (en) 2004-07-29 2006-02-02 Roger Stier E Oral compositions which mask the bitter taste of a bitter-tasting agent
EP1815015B1 (en) 2004-11-18 2012-05-23 Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke Stiftung des Öffentlichen Rechts Agonists of bitter taste receptors and uses thereof
US20060222709A1 (en) * 2005-03-18 2006-10-05 Agi Therapeutics Research Ltd. Metformin methods and formulations for treating chronic constipation
CN101166742B (zh) 2005-04-28 2011-07-13 味之素株式会社 新型内酰胺化合物
US20060269617A1 (en) 2005-05-26 2006-11-30 Suracell, Inc. Supplement compositions and method of use for enhancement of insulin sensitivity
CN101416055A (zh) 2005-06-22 2009-04-22 塞诺米克斯公司 被咖啡中的苦味分子(绿原酸内酯)激活的人t2r受体的鉴定和用于鉴定人苦味调节剂的相关测定法
BRPI0615410A2 (pt) * 2005-08-30 2013-02-13 Nicholas Piramal India Ltd composiÇço farmacÊutica de liberaÇço prolongada de metformina e processo para produÇço da mesma
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
US20070104805A1 (en) 2005-11-01 2007-05-10 Udell Ronald G Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
JP2007215162A (ja) 2006-01-11 2007-08-23 Canon Inc 情報処理装置及びその制御方法、プログラム、記憶媒体
US20070207227A1 (en) 2006-02-23 2007-09-06 Conopco, Inc., D/B/A Unilever, A Corporation Of New York Appetite suppressant compositions
WO2007116404A2 (en) 2006-04-10 2007-10-18 Bar-Ilan University Cucurbitacin glucosides and use thereof in treating cancer
CA2551706A1 (en) 2006-06-27 2007-12-27 Innovative Life Sciences Corporation Herbal product comprising cinnamon and bitter melon
CN100596277C (zh) 2006-07-10 2010-03-31 博仲盛景医药技术（北京）有限公司 一种促进肠胃蠕动的药物组合物
EP2051723A1 (en) 2006-08-17 2009-04-29 Unilever N.V. Processes for production of hoodia plant extracts containing steroidal glycosides
WO2008022875A1 (en) 2006-08-24 2008-02-28 Unilever N.V. Process for preparing a composition comprising steroidal glycosides
EP2064226A4 (en) 2006-09-05 2010-03-31 Senomyx Inc NOVEL HUMAN T2R HT2R50 RECEPTOR HAPLOTYPE AND USE THEREOF IN ANALYZES TO IDENTIFY HUMAN MODULATORS OF BITTER TASTE
EP1975612A1 (en) 2007-03-29 2008-10-01 Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke-Stiftung des öffentlichen Rechts- Vertreten durch den Stiftungsvorstand Agonists of bitter taste receptors and uses thereof
EP1975611A1 (en) 2007-03-29 2008-10-01 Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke-Stiftung des öffentlichen Rechts- Vertreten durch den Stiftungsvorstand Agonists of bitter taste receptors and uses thereof
US20090042813A1 (en) 2007-08-10 2009-02-12 Sergey Michailovich Melnikov Hoodia extract oil compositions comprising medium chain triglycerides
WO2009053980A2 (en) 2007-10-24 2009-04-30 Arava Hoodia Growers A. C. S. Ltd. An improved appetite suppressant
US20100330205A1 (en) 2008-01-29 2010-12-30 Nakamori Pharmaceutical Co., Ltd. Pharmaceutical composition
US9844224B2 (en) 2008-05-23 2017-12-19 Givaudan Sa Bitter alkaloid containing consumables comprising bitter blockers
EP2300830B1 (en) 2008-06-13 2015-05-20 Givaudan SA Methods of identifying modulators of the bitter taste receptor tas2r44
EP2329271B1 (en) 2008-08-29 2012-06-20 Givaudan SA Methods to identify modulators
TWI469779B (zh) 2008-08-29 2015-01-21 Suntory Holdings Ltd Novel epigallocatechin gallate 4, and its vascular endothelial function enhancer
WO2010060198A1 (en) 2008-11-26 2010-06-03 West Central Envirotech Inc. Composition and method for controlling insects
CA2748729A1 (en) 2009-01-03 2010-07-08 Shizuoka Prefecture Public University Corporation Sulfated c-glycoside, method for isolating same and method for synthesizing same
US8709745B2 (en) 2009-07-28 2014-04-29 Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke Methods for isolating ligands of the human bitter taste receptor TAS2R49
EP2490695B1 (en) 2009-10-21 2013-11-20 Wisconsin Alumni Research Foundation Method of preventing type 1 diabetes
RU2012127779A (ru) 2009-12-04 2014-01-20 Колгейт-Палмолив Компани КОМПОЗИЦИЯ ДЛЯ УХОДА ЗА ПОЛОСТЬЮ РТА, СОДЕРЖАЩАЯ ЭКСТРАКТЫ ИЗ Garcinia mangostana L., И СВЯЗАННЫЕ С НЕЙ СПОСОБЫ
EP2345646A1 (en) 2010-01-14 2011-07-20 InterMed Discovery GmbH Use of tricyclic sesquiterpene lactones in the treatment of obesity and related diseases and non-therapeutic treatable conditions
US20110293753A1 (en) 2010-05-28 2011-12-01 Louis Bellafiore Tocotrienol Compositions
GB201009873D0 (en) 2010-06-14 2010-07-21 Univ Leuven Kath Method for hydrogenation of isoalpha-acids (isohumulones) to hexahydro-iso-alpha-acids (hexahydro-isohumulones) by using heterogeneous ruthenium
EP2397039A1 (en) 2010-06-21 2011-12-21 Abbott Laboratories Compositions for delaying progression of diabetes using Salacia oblonga extract
CN101978956B (zh) * 2010-10-13 2012-03-28 北京京丰制药有限公司 盐酸二甲双胍肠溶片及其制备方法
PT2661266T (pt) * 2011-01-07 2020-11-30 Anji Pharma Us Llc Terapias com base em ligandos do recetor quimiossensorial
SG10201901922VA (en) 2012-01-06 2019-04-29 Elcelyx Therapeutics Inc Compositions and methods for treating metabolic disorders
CN103768071B (zh) * 2012-10-23 2016-08-17 中国医药工业研究总院 一种治疗糖尿病的口服制剂

Also Published As

Publication number Publication date
BR112015016111A2 (pt) 2020-01-28
SG10201705437SA (en) 2017-07-28
HK1214966A1 (zh) 2016-08-12
MX389344B (es) 2025-03-20
CN110051638A (zh) 2019-07-26
MX376822B (es) 2025-03-07
AU2014203942A1 (en) 2015-07-16
PH12015501520A1 (en) 2015-09-21
SG11201505240QA (en) 2015-08-28
AU2014203942B2 (en) 2019-01-03
NZ709525A (en) 2020-07-31
IL239722B (en) 2022-04-01
EP2941245B1 (en) 2024-06-26
ZA201504858B (en) 2018-12-19
EP4410380A2 (en) 2024-08-07
CN105101956B (zh) 2018-12-07
CL2015001914A1 (es) 2015-09-04
KR102229492B1 (ko) 2021-03-17
KR20150103079A (ko) 2015-09-09
US20140193498A1 (en) 2014-07-10
JP6333855B2 (ja) 2018-05-30
MX2015008625A (es) 2015-09-23
CN110051638B (zh) 2022-02-01
US20200093750A1 (en) 2020-03-26
JP2016504384A (ja) 2016-02-12
MX2020011594A (es) 2022-01-13
CN105101956A (zh) 2015-11-25
CA2896864A1 (en) 2014-07-10
CA2896864C (en) 2021-04-20
AR094374A1 (es) 2015-07-29
EA039530B1 (ru) 2022-02-08
EA201591085A1 (ru) 2015-12-30
EP2941245A1 (en) 2015-11-11
WO2014107617A1 (en) 2014-07-10
EP4410380A3 (en) 2024-10-23
IL239722A0 (en) 2015-08-31
US20250000804A1 (en) 2025-01-02

Similar Documents

Publication Publication Date Title
MX2015008625A (es) Composicion de liberacion demorada que comprende biguanida.
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
ECSP19021223A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
CL2016001120A1 (es) Compuestos derivados de pirrolo1,2-f1,2,4triazina ,composición farmacéutica que los comprende y su uso en el tratamiento de una infección por virus sincicial compuestos intermediarios. pct
CO2018000660A2 (es) Compuestos derivados del (3β)-cholest-5-en-3-alquil-3-ol y (3β)-cholest-3-alquil-3-ol
UY35300A (es) Formulación de combinación de dos compuestos antivirales
CU24397B1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b
CU20170077A7 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos, composiciones y combinaciones que lo comprende
DOP2016000233A (es) MODULADORES ALOSTÉRICOS DE PROTElNA NÚCLEO DE HEPATITIS B
PH12017502001A1 (en) Amido-substituted cyclohexane derivatives
CR20160119A (es) Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística
GT201500247A (es) Imidazopiridazinas sustituidas
MX2016011810A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
GT201300254A (es) Triazolopiridinas
PH12015501096A1 (en) Composition for immediate and extended release
GT201400261A (es) Solicitud pct face nacional novedosas n-piridinil amidas ciclicas sustituidas como inhibidores de quinasa
MX376115B (es) Composiciones para el cuidado personal con dos fases benéficas.
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
MX2016008665A (es) Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo.
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
CL2015002466A1 (es) Formulaciones de compuestos orgánicos
CL2018001493A1 (es) Nuevos derivados de fenilo
CR20160016A (es) Pirazolpiridinas sustituidas
BR112017009289A2 (pt) métodos de administrar composições de amantadina
MX2017008983A (es) Composición farmaceútica de sulfonamida.